Topicals
An emollient is an ingredient found in topical applications to soften and soothe skin. They are valuable and inexpensive treatment options for many individuals with mild to moderate psoriasis. When psoriasis is more severe, topicals are likely to be combined with oral medications, phototherapy, or biologics.
Emollients relieve symptoms of dryness and irritation while assisting in managing overgrowth and the shedding of skin cells that occurs with psoriasis. It can help soften plaques and cracks, enhance the skin’s ability to hold water and create a barrier that protects skin from bacteria and other irritants. As a result, this improves the skin’s barrier function and relieves inflammation. Emollients can be found in many different forms such as creams, lotions, ointments, foams, sprays, gels and shampoos and can be used directly on your skin.
Humectant and occlusive agents are the two key ingredients in a moisturizing product. The combination of ingredients determines the use and consistency of a product. Humectant enhances the skin’s ability to hold water and an occlusive agent slows water loss by creating a protective barrier on the skin’s surface. These ingredients can feel thick and sticky, so manufacturers combine them with other substances to improve their ability to spread and penetrate the skin. Thicker products are often a good choice for people with psoriasis as they can prevent dryness but it’s best to consult with a physician to determine the ideal course of treatment.
When choosing a moisturizer for psoriasis, you may also want to consider the smell, ease of use, and the ingredients in the product. Hypoallergenic products (a product containing fewer allergy-producing substances) are commonly used as they less likely to irritate the skin. Some fragrances and chemicals found in moisturizers could further aggravate skin instead of relieving symptoms so it may be best to look for a fragrance-free lotion.
Dosage Form Considerations
| Vehicle | Consistency | Quality | Speed of absorption/evaporation after application to the skin | Useful for areas with hair | Other considerations |
|---|---|---|---|---|---|
| Ointment | Viscous | Greasy | Slow | No | Provides an occlusive layer when applied to skin |
| Gel | Thick | Non-greasy | Moderate | No | Cooling sensation when applied to skin |
| Cream | Moderate | Non-greasy to mildly greasy | Quick | Maybe | |
| Lotion | Thin | Non-greasy | Very Quick | Yes | Cooling sensation when applied to skin |
| Foam | Thin | Non-greasy | Very Quick | Yes | Spreads easily |
| Solution | Thin | Non-greasy | Very Quick | Yes | |
| Scalp solution | Very Thin | Non-greasy | Very Quick | Yes | |
| Spray | Very Thin | Non-greasy | Very Quick | Maybe | |
| Shampoo | Very Thin | Non-greasy | Quick | Yes | Must be left in place for 10-15 minutes before rinsing (follow product instructions) |
List of Prescription Topical Treatment
Topical Corticosteroids (e.g., betamethasone & mometasone)
How Does It Work?
Corticosteroids applied topically have the ability to decrease inflammation in the skin in many conditions, including psoriasis.
How Is It Used?
Topical corticosteroids are typically prescribed to be applied to psoriatic plaques twice daily. Topical corticosteroids are available in a variety of different potencies (strengths). Your doctor may prescribe a certain strength topical corticosteroid depending on the thickness of psoriasis plaques and their location on your body.
What are the possible side effects?
The most common side effect of topical corticosteroids is an initial mild burning or stinging feeling after application. Long-term use of strong corticosteroids can result in thinning of the skin. This should be monitored by you and your physician.
Any Other Important Considerations?
Avoid covering the steroids with bandages or plastic wrap unless instructed to do so by your doctor.
What Medications Interact With This Treatment?
N/A
What Provinces and Territories List It On Formulary?
Varies depending on specific corticosteroid.
Product Monograph
The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Vitamin D3 analogues (Dovonex® & Silkis®)
How Does It Work?
Vitamin D3 analogues work by regulating skin cell production and proliferation (buildup), which is abnormal in psoriasis. Vitamin D3 analogues used to treat psoriasis include calcitriol (Silkis®) and calcipotriol (Dovonex®).
How Is It Used?
Vitamin D3 analogues are available as topical ointments and are applied as to the affected area of skin once or twice daily as directed by physician.
What are the possible side effects?
The most common side effect of vitamin D3 analogues is a temporary burning or stinging sensation when applied to the skin.
Any Other Important Considerations?
N/A
What Medications Interact With This Treatment?
N/A
Product Monograph
The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Combination vitamin D3 analogues & corticosteroids (Dovobet® & Enstilar™)
How Does It Work?
Combination vitamin D3 analogues and corticosteroids work by targeting key aspects of psoriasis. The vitamin D3 analogue (calcipotriol) helps control inflammation and regulate excessive skin cell growth, while the corticosteroid (betamethasone) reduces inflammation, redness, and itching. Together, they are more effective than either treatment alone in controlling psoriasis symptoms.
How Is It Used?
Combination products are applied topically to the affected areas of skin, usually once daily or as directed by a physician. The specific formulation (foam, gel, or ointment) may vary depending on the location and severity of psoriasis.
What are the possible side effects?
Common side effects include mild skin irritation, burning, itching, or redness at the application site. Due to the corticosteroid component, prolonged use may lead to skin thinning (atrophy), stretch marks, or increased sensitivity. In rare cases, excessive use may affect calcium levels or cause systemic steroid effects.
Any Other Important Considerations?
These medications are typically used for limited periods to reduce the risk of side effects from long-term corticosteroid use. They should not be applied to the face, groin, or underarms unless directed by a physician. Patients should follow prescribed amounts carefully and avoid covering treated areas unless instructed.
What Medications Interact With This Treatment?
Use with other topical corticosteroids or vitamin D products should be monitored to avoid increased risk of side effects. Caution is advised when used alongside medications that affect calcium metabolism. Always inform your healthcare provider of all medications being used.
Product Monograph
The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here
Topical retinoids - (Tazarotene)
How Does It Work?
The exact mechanism of tazarotene is unknown. It is thought to play a role in the differentiation of skin (i.e., it helps to control the multiplication of skin cells), and it may also help to regulate the immune system.
How Is It Used?
Tazarotene comes in both a gel and cream formulation. Typically, it is recommended to be applied to the affected area of skin once a day, usually at night. Improvement is typically noted within two months of treatment.
What are the possible side effects?
The most common side effect of topical retinoids is skin irritation. Redness, a burning sensation, dry skin, and skin shedding are commonly experienced with tazarotene, but these side effects tend to subside after a few weeks of treatment.
Any Other Important Considerations?
Tazarotene cannot be used during pregnancy.
Avoid unprotected exposure to sunlight and sunlamps as this product may increase the sensitivity of skin to ultraviolet light.
What Medications Interact With This Treatment?
No known significant drug interactions.
Product Monograph
The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Anthralin & Tars
How Does It Work?
The exact mechanism of anthralin and tars are unknown but they are thought to decrease the skin inflammation that is associated with psoriasis. Coal tar loosens and softens scales and crusts.
How Is It Used?
Anthralin:
Generally applied once daily or as directed by a doctor or pharmacist. When first starting to use anthralin, a short contact time of 5 – 10 minutes of the cream may be advised during the first week of treatment. Contact time can be gradually increased to up to 30 minutes, as tolerated by the skin. Anthralin can be removed by washing or showering.
When applying, gloves may be used to avoid staining of fingers and nails. Apply directly to plaques; rub in gently and avoid application to unaffected skin. Petroleum jelly may be used around the edges of the plaque to prevent irritation of unaffected skin.
Coal tar:
For scalp psoriasis, coal tar may be painted sparingly to the lesions 3-12 hours before shampooing.
For body psoriasis, apply coal tar to the lesions at bedtime.
Wash hands before and after application.
What are the possible side effects?
Anthralin: temporary skin irritation, temporary hair discolouration, temporary nail discolouration, temporary skin discolouration.
Coal tar: temporary skin irritation, increased skin sensitivity to light.
Any Other Important Considerations?
Anthralin is irritating to surrounding normal skin. It also stains skin and fabrics.
Coal tar has an odour and can stain skin and hair.
What Medications Interact With This Treatment?
N/A
Product Monograph
N/A
The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Halobetasol propionate and tazarotene (DUOBRII®)
How Does It Work?
DUOBRII® is a lotion used on the skin to improve the signs and symptoms of psoriasis in adults.
DUOBRII® is a combination of two different medications. It contains halobetasol propionate, a corticosteroid, and tazarotene, a topical retinoid. Halobetasol propionate has the ability to decrease inflammation in the skin. Tazarotene is thought to work by helping with the normal growth of skin cells and by reducing inflammation.
How Is It Used?
Apply a thin layer once a day to affected skin. Rub in gently and wash your hands after application. Once your psoriasis is better, stop using DUOBRII® . It may then be used on and off as necessary, or as directed by your physician.
What are the possible side effects?
The most common side effects include contact dermatitis, a skin rash, or sores. Please consult the Product Monograph for more side effects.
Prolonged use of this product may cause the adrenal glands to become suppressed. Only use DUOBRII® under the supervision of a physician.
Any Other Important Considerations?
Do not use DUOBRII® :
- If you are allergic to halobetasol propionate, tazarotene or any of the other ingredients found in DUOBRII®.
- If you are allergic to other corticosteroids or retinoic compounds.
- On some other skin conditions (such as dermatitis, skin reactions after a vaccine, and infections).
- If you are pregnant or if you think you might be pregnant.
Coal tar has an odour and can stain skin and hair.
What Medications Interact With This Treatment?
No known significant drug interactions.
Product Monograph
https://pdf.hres.ca/dpd_pm/00066402.PDF
The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Halobetasol propionate lotion (Bryhali™)
How Does It Work?
Bryhali is a topical steroid, meaning it stops inflammation in areas that it is applied to which is helpful in treating plaque psoriasis.
How Is It Used?
Bryhali is a cream that is applied to areas of skin affected by plaque psoriasis. Bryhali should typically not be used for more than 8 weeks. There are several areas of the skin Bryhali should not be applied to because of risk of skin damage, so always talk to your doctor prior to using Bryhali to establish the appropriate amount to use and appropriate area of use.
What are the possible side effects?
Possible side effects of Bryhali include reaction of the skin the cream is applied to, including change in appearance of the skin as well as burning or itching skin. Less common side effects include increased risk of infection, cough, and high blood pressure. To obtain a comprehensive list of all potential side effects, talk to your doctor or pharmacist.
Any Other Important Considerations?
Bryhali should typically not be used for more than 8 weeks. Bryhali should typically be used with caution if you have any skin infections or history of high blood pressure
What Medications Interact With This Treatment?
There are no known drug interactions with Bryhali, but always check with your doctor prior to starting Bryhali to rule out any possibility of drug interaction.
More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.
NIHB stands for non-insured health benefits.
This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.
Product Monograph
https://pdf.hres.ca/dpd_pm/00060714.PDF
The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Roflumilast (ZORYVE™)
Product Monograph
https://pdf.hres.ca/dpd_pm/00060714.PDF
The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
How Does It Work?
Roflumilast is a non-steroid selective inhibitor of phosphodiesterase 4 (PDE4), used for the topical treatment of plaque psoriasis, including treatment of psoriasis in the intertriginous areas, in patients 12 years of age and older.
How Is It Used?
Apply roflumilast topically once a day to affected areas of the skin and rub in completely. Wash hands after application unless hands are the affected areas being treated.
If deemed medically necessary to use during breast-feeding, use roflumilast on the smallest area of the skin for the shortest duration possible. Do not apply roflumilast directly to the nipple and areola to avoid direct infant exposure.
Roflumilast is for topical use only and not for ophthalmic, oral, or intravaginal use.
What are the possible side effects?
The most common adverse drug reactions reported in clinical trials among patients with plaque psoriasis 12 years of age and older are diarrhea and headache. To obtain a comprehensive list of all known potential side effects of roflumilast, talk to your doctor or pharmacist.
Any Other Important Considerations?
Roflumilast is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C), and patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredients, or components of the container.
Roflumilast should not be used during labor and delivery. Roflumilast should only be used by a breast-feeding mother if deemed medically necessary, considering a potential risk to the baby. To minimize potential exposure to the breastfed infant via breast milk, use roflumilast on the smallest area of skin and for the shortest duration possible while breastfeeding. Do not to apply roflumilast directly to the nipple and areola to avoid direct infant exposure.
What Medications Interact With This Treatment?
No formal drug-drug interaction studies were conducted with roflumilast. For a complete list of medications that may interact with roflumilast and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.
Patient Support Program
ZORYVE Assist
www.zoryveassist.ca
1-855-ZORYVE9 (1-855-967-9839)
M-F 8am-8pm EST
Tapinarof (NDUVRA®)
How Does It Work?
Tapinarof (NDUVRA®) is a cream used on the skin to improve the signs and symptoms of plaque psoriasis in adults.
NDUVRA contains tapinarof, which belongs to a class of medicines known as aryl hydrocarbon receptor (AhR) agonists. These medicines act on receptors in the skin that are involved in inflammatory pathways related to psoriasis.
How Is It Used?
Tapinarof is to be used under the direction of your doctor.
Apply a thin layer once a day to affected skin areas.
- Apply the cream to clean, dry skin
- Wash your hands after application, unless you are treating the hands or fingernails.
- Avoid applying the cream to unaffected skin.
- Avoid swimming, bathing, showering, or strenuous activity for at least 2 hours after application.
If you miss a dose, apply it as soon as possible on the same day, then continue your regular schedule the next day. Do not apply more than once daily to make up for a missed dose.
What are the possible side effects?
The most common side effects may include folliculitis (inflammation around hair follicles, sore throat or nasal symptoms, skin rash or irritation, headache, itching, or flu.
Only use NDUVRA under the supervision of a physician.
To obtain a comprehensive list of all potential side effects, talk to your doctor or pharmacist.
Any Other Important Considerations?
NDUVRA is for external topical use only. It should not be used in the eyes, mouth, or vagina.
Use this medication only as directed by your physician.
What Medications Interact With This Treatment?
No clinically significant drug interactions have been identified.
Product Monograph
https://pdf.hres.ca/dpd_pm/00081644.PDF
The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Public Drug Program Formulary Tables
| Province | Class | Generic name | Drug Name | Psoriasis | Psoriatic arthritis | GPP | monograph |
|---|---|---|---|---|---|---|---|
| Alberta | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | https://pdf.hres.ca/dpd_pm/00070861.PDF | |
| Alberta | Systemic Drugs | Acitretin | Soriatane® | Yes | N/A | https://pdf.hres.ca/dpd_pm/00046848.PDF | |
| Alberta | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00067414.PDF | |
| Alberta | Systemic Drugs | Apremilast | Otezla® | No | No | https://pdf.hres.ca/dpd_pm/00057499.PDF | |
| Alberta | Biologics and Biosimilars | Bimekizumab | Bimzelx | Yes – EDS | No | https://pdf.hres.ca/dpd_pm/00074908.PDF | |
| Alberta | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – EDS | N/A | https://pdf.hres.ca/dpd_pm/00075300.PDF | |
| Alberta | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | SA | https://pdf.hres.ca/dpd_pm/00053920.PDF | |
| Alberta | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | Yes | N/A | https://pdf.hres.ca/dpd_pm/00055197.PDF | |
| Alberta | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | Yes | N/A | https://pdf.hres.ca/dpd_pm/00034364.PDF | |
| Alberta | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | Yes | N/A | https://pdf.hres.ca/dpd_pm/00065877.PDF | |
| Alberta | Systemic Drugs | Methotrexate | Yes | Yes | |||
| Alberta | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00060454.PDF | |
| Alberta | Biologics and Biosimilars | Golimumab | Simponi® | SA | SA | https://pdf.hres.ca/dpd_pm/00074084.PDF | |
| Alberta | Biologics and Biosimilars | Guselkumab | Tremfya® | Yes – EDS | Yes – EDS | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| Alberta | Prescription Topical Treatments | Halobetasol propionate and tazarotene | Duobrii® | SA | N/A | https://pdf.hres.ca/dpd_pm/00066402.PDF | |
| Alberta | Prescription Topical Treatments | Halobetasol propionate | Bryhali | N/A | |||
| Alberta | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00075118.PDF | |
| Alberta | Biologics and Biosimilars | Ixekizumab | Taltz® | SA | SA | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| Alberta | Systemic Drugs | Cyclosporine | Neoral | SA | N/A | ||
| Alberta | Biologics and Biosimilars | Risankizumab | Skyrizi™ | SA | No | https://pdf.hres.ca/dpd_pm/00075159.PDF | |
| Alberta | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | SA | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| Alberta | Prescription Topical Treatments | Roflumilast | Zoryve | No | N/A | ||
| Alberta | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | SA | N/A | https://pdf.hres.ca/dpd_pm/00064464.PDF | |
| Alberta | Systemic Drugs | Tofacitinib | Xeljanz® | N/A | No | https://pdf.hres.ca/dpd_pm/00075206.PDF | |
| Alberta | Prescription Topical Treatments | Topical Retinoids (Tazarotene) | Arazlo | Yes | N/A | No information available | |
| Alberta | Systemic Drugs | Upadacitinib | Rinvoq® | N/A | SA | https://pdf.hres.ca/dpd_pm/00073108.PDF | |
| Alberta | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| Alberta | Prescription Topical Treatments | Vitamin_D3_Analogues(Calcipotriol ) | Dovonex® | Yes | N/A | https://pdf.hres.ca/dpd_pm/00064010.PDF | |
| Alberta | Prescription Topical Treatments | Vitamin_D3_Analogues(Calcitriol) | Silkis® | No | N/A | https://pdf.hres.ca/dpd_pm/00041695.PDF | |
| Alberta | Biologics and Biosimilars | spesolimab | Spevigo | N/A | N/A | No | |
| British Columbia | Systemic Drugs | Acitretin | Soriatane® | Yes | N/A | https://pdf.hres.ca/dpd_pm/00046848.PDF | |
| British Columbia | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00067414.PDF | |
| British Columbia | Systemic Drugs | Apremilast | Otezla® | No | No | https://pdf.hres.ca/dpd_pm/00057499.PDF | |
| British Columbia | Biologics and Biosimilars | bimekizumab | Bimzelx | Yes – EDS | No | https://pdf.hres.ca/dpd_pm/00074908.PDF | |
| British Columbia | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – EDS | N/A | https://pdf.hres.ca/dpd_pm/00075300.PDF | |
| British Columbia | Biologics and Biosimilars | Certolizumab-pergol | Cimzia® | No | SA | https://pdf.hres.ca/dpd_pm/00053920.PDF | |
| British Columbia | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | Yes | N/A | https://pdf.hres.ca/dpd_pm/00055197.PDF | |
| British Columbia | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | No | N/A | https://pdf.hres.ca/dpd_pm/00034364.PDF | |
| British Columbia | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | No | N/A | https://pdf.hres.ca/dpd_pm/00065877.PDF | |
| British Columbia | Systemic Drugs | Methotrexate | Yes | Yes | |||
| British Columbia | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00060454.PDF | |
| British Columbia | Biologics and Biosimilars | Golimumab | Simponi® | SA | SA | https://pdf.hres.ca/dpd_pm/00074084.PDF | |
| British Columbia | Biologics and Biosimilars | guselkumab | Tremfya® | Yes – EDS | Yes – EDS | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| British Columbia | Prescription Topical Treatments | tazarotene and holobetasol | Duobrii® | SA | N/A | https://pdf.hres.ca/dpd_pm/00066402.PDF | |
| British Columbia | Prescription Topical Treatments | Halobetasol propionate | Bryhali | N/A | |||
| British Columbia | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00075118.PDF | |
| British Columbia | Biologics and Biosimilars | Ixekizumab | Taltz® | SA | SA | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| British Columbia | Systemic Drugs | Cyclosporine | Neoral | SA | N/A | ||
| British Columbia | Biologics and Biosimilars | Risankizumab | Skyrizi™ | SA | No | https://pdf.hres.ca/dpd_pm/00075159.PDF | |
| British Columbia | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | SA | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| British Columbia | Prescription Topical Treatments | Roflumilast | Zoryve | No | N/A | ||
| British Columbia | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | No | N/A | https://pdf.hres.ca/dpd_pm/00064464.PDF | |
| British Columbia | Systemic Drugs | Tofacitinib | Xeljanz® | N/A | SA | https://pdf.hres.ca/dpd_pm/00075206.PDF | |
| British Columbia | Prescription Topical Treatments | Topical Retinoids (Tazarotene) | Arazlo | No | N/A | No information available | |
| British Columbia | Systemic Drugs | Upadacitinib | Rinvoq® | N/A | No | https://pdf.hres.ca/dpd_pm/00073108.PDF | |
| British Columbia | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| British Columbia | Prescription Topical Treatments | Vitamin_D3_Analogues(Calcipotrial) | Dovonex® | Yes | N/A | https://pdf.hres.ca/dpd_pm/00064010.PDF | |
| British Columbia | Prescription Topical Treatments | Vitamin_D3_Analogues(Calcitriol) | Silkis® | No | N/A | https://pdf.hres.ca/dpd_pm/00041695.PDF | |
| British Columbia | Systemic Drugs | Abatacept | Orencia | N/A | No | ||
| British Columbia | Biologics and Biosimilars | spesolimab | Spevigo | N/A | No | No | |
| Manitoba | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | https://pdf.hres.ca/dpd_pm/00070861.PDF | |
| Manitoba | Systemic Drugs | Acitretin | Soriatane® | Yes | N/A | https://pdf.hres.ca/dpd_pm/00046848.PDF | |
| Manitoba | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00067414.PDF | |
| Manitoba | Systemic Drugs | Apremilast | Otezla | No | No | https://pdf.hres.ca/dpd_pm/00057499.PDF | |
| Manitoba | Biologics and Biosimilars | Bimekizumab | Bimzelx | Yes - EDS | No | https://pdf.hres.ca/dpd_pm/00074908.PDF | |
| Manitoba | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – EDS | https://pdf.hres.ca/dpd_pm/00053920.PDF | |
| Manitoba | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | Yes | N/A | https://pdf.hres.ca/dpd_pm/00055197.PDF | |
| Manitoba | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | Yes | N/A | https://pdf.hres.ca/dpd_pm/00034364.PDF | |
| Manitoba | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | Yes | N/A | https://pdf.hres.ca/dpd_pm/00065877.PDF | |
| Manitoba | Systemic Drugs | Cyclosporine | Neoral | SA | N/A | https://pdf.hres.ca/dpd_pm/00069722.PDF | |
| Manitoba | Systemic Drugs | Methotrexate | Yes | Yes | |||
| Manitoba | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00060454.PDF | |
| Manitoba | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – EDS | https://pdf.hres.ca/dpd_pm/00074084.PDF | |
| Manitoba | Biologics and Biosimilars | Guselkumab | Tremfya® | Yes - EDS | Yes - EDS | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| Manitoba | Prescription Topical Treatments | Halobetasol propionate and tazarotene | Duobrii® | Yes | N/A | https://pdf.hres.ca/dpd_pm/00066402.PDF | |
| Manitoba | Prescription Topical Treatments | Halobetasol propionate | Bryhali | N/A | |||
| Manitoba | Prescription Topical Treatments | Roflumilast | Zoryve | No | N/A | ||
| Manitoba | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00075118.PDF | |
| Manitoba | Biologics and Biosimilars | Ixekizumab | Taltz® | SA | SA | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| Manitoba | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – EDS | N/A | https://pdf.hres.ca/dpd_pm/00075300.PDF | |
| Manitoba | Biologics and Biosimilars | Risankizumab | Skyrizi™ | SA | No | https://pdf.hres.ca/dpd_pm/00075159.PDF | |
| Manitoba | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | SA | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| Manitoba | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | SA | N/A | https://pdf.hres.ca/dpd_pm/00064464.PDF | |
| Manitoba | Systemic Drugs | Tofacitinib | Xeljanz® | N/A | SA | https://pdf.hres.ca/dpd_pm/00075206.PDF | |
| Manitoba | Prescription Topical Treatments | Topical Retinoids (Tazarotene) | Arazlo | Yes | N/A | No information available | |
| Manitoba | Systemic Drugs | Upadacitinib | Rinvoq® | N/A | SA | https://pdf.hres.ca/dpd_pm/00073108.PDF | |
| Manitoba | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| Manitoba | Prescription Topical Treatments | Vitamin_D3_Analogues (Calcipotriol) | Dovonex® | Yes | N/A | https://pdf.hres.ca/dpd_pm/00064010.PDF | |
| Manitoba | Prescription Topical Treatments | Vitamin_D3_Analogues(Calcitriol) | Silkis® | No | N/A | https://pdf.hres.ca/dpd_pm/00041695.PDF | |
| Manitoba | Biologics and Biosimilars | spesolimab | Spevigo | N/A | N/A | No | |
| New Brunswick | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | https://pdf.hres.ca/dpd_pm/00070861.PDF | |
| New Brunswick | Systemic Drugs | Acitretin | Soriatane | Yes | N/A | https://pdf.hres.ca/dpd_pm/00046848.PDF | |
| New Brunswick | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00067414.PDF | |
| New Brunswick | Systemic Drugs | Apremilast | Otezla® | No | No | https://pdf.hres.ca/dpd_pm/00057499.PDF | |
| New Brunswick | Biologics and Biosimilars | Bimekizumab | Bimzelx | SA | SA | https://pdf.hres.ca/dpd_pm/00074908.PDF | |
| New Brunswick | Biologics and Biosimilars | Brodalumab | Siliq™ | SA | N/A | https://pdf.hres.ca/dpd_pm/00075300.PDF | |
| New Brunswick | Prescription Topical Treatments | Halobetasol propionate | Bryhali | N/A | https://pdf.hres.ca/dpd_pm/00041466.PDF | ||
| New Brunswick | Prescription Topical Treatments | Roflumilast | Zoryve | No | N/A | ||
| New Brunswick | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | SA | https://pdf.hres.ca/dpd_pm/00053920.PDF | |
| New Brunswick | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | Yes | N/A | https://pdf.hres.ca/dpd_pm/00055197.PDF | |
| New Brunswick | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | Yes | N/A | https://pdf.hres.ca/dpd_pm/00034364.PDF | |
| New Brunswick | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | Yes | N/A | https://pdf.hres.ca/dpd_pm/00065877.PDF | |
| New Brunswick | Systemic Drugs | Cyclosporine | Neoral | Yes | N/A | ||
| New Brunswick | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00060454.PDF | |
| New Brunswick | Biologics and Biosimilars | Golimumab | Simponi® | SA | SA | https://pdf.hres.ca/dpd_pm/00074084.PDF | |
| New Brunswick | Biologics and Biosimilars | Guselkumab | Tremfya® | Yes – S/A | Yes – S/A | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| New Brunswick | Prescription Topical Treatments | Halobetasol propionate and tazarotene | Duobrii® | Yes | N/A | https://pdf.hres.ca/dpd_pm/00066402.PDF | |
| New Brunswick | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00075118.PDF | |
| New Brunswick | Biologics and Biosimilars | Ixekizumab | Taltz® | SA | SA | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| New Brunswick | Systemic Drugs | Methotrexate | Yes | Yes | |||
| New Brunswick | Biologics and Biosimilars | Risankizumab | Skyrizi™ | SA | No | https://pdf.hres.ca/dpd_pm/00075159.PDF | |
| New Brunswick | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | SA | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| New Brunswick | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | SA | N/A | https://pdf.hres.ca/dpd_pm/00064464.PDF | |
| New Brunswick | Systemic Drugs | Tofacitinib | Xeljanz® | N/A | No | https://pdf.hres.ca/dpd_pm/00075206.PDF | |
| New Brunswick | Prescription Topical Treatments | Topical Retinoids (Tazarotene) | Arazlo | Yes | N/A | ||
| New Brunswick | Systemic Drugs | Upadacitinib | Rinvoq® | N/A | SA | https://pdf.hres.ca/dpd_pm/00073108.PDF | |
| New Brunswick | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| New Brunswick | Prescription Topical Treatments | Vitamin_D3_Analogues (Calcipotriol) | Dovonex® | Yes | N/A | https://pdf.hres.ca/dpd_pm/00064010.PDF | |
| New Brunswick | Prescription Topical Treatments | Vitamin_D3_Analogues(Calcitriol) | Silkis® | Yes | N/A | https://pdf.hres.ca/dpd_pm/00041695.PDF | |
| New Brunswick | Biologics and Biosimilars | spesolimab | Spevigo | No | No | No | |
| Newfoundland and Labrador | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | https://pdf.hres.ca/dpd_pm/00070861.PDF | |
| Newfoundland and Labrador | Systemic Drugs | Acitretin | Soriatane® | Yes | N/A | https://pdf.hres.ca/dpd_pm/00046848.PDF | |
| Newfoundland and Labrador | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00067414.PDF | |
| Newfoundland and Labrador | Systemic Drugs | Apremilast | Otezla® | No | No | https://pdf.hres.ca/dpd_pm/00057499.PDF | |
| Newfoundland and Labrador | Biologics and Biosimilars | Bimekizumab | Bimzelx | SA | SA | https://pdf.hres.ca/dpd_pm/00074908.PDF | |
| Newfoundland and Labrador | Biologics and Biosimilars | Brodalumab | Siliq™ | SA | SA | https://pdf.hres.ca/dpd_pm/00075300.PDF | |
| Newfoundland and Labrador | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – S/A | https://pdf.hres.ca/dpd_pm/00053920.PDF | |
| Newfoundland and Labrador | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | SA | N/A | https://pdf.hres.ca/dpd_pm/00055197.PDF | |
| Newfoundland and Labrador | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | No | N/A | https://pdf.hres.ca/dpd_pm/00034364.PDF | |
| Newfoundland and Labrador | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | Yes | N/A | https://pdf.hres.ca/dpd_pm/00065877.PDF | |
| Newfoundland and Labrador | Systemic Drugs | Cyclosporine | Neoral | Yes | N/A | ||
| Newfoundland and Labrador | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00060454.PDF | |
| Newfoundland and Labrador | Biologics and Biosimilars | Golimumab | Simponi® | N/A | SA | https://pdf.hres.ca/dpd_pm/00074084.PDF | |
| Newfoundland and Labrador | Biologics and Biosimilars | Guselkumab | Tremfya® | SA | SA | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| Newfoundland and Labrador | Prescription Topical Treatments | Halobetasol propionate and tazarotene | Duobrii® | SA | N/A | https://pdf.hres.ca/dpd_pm/00066402.PDF | |
| Newfoundland and Labrador | Prescription Topical Treatments | Halobetasol propionate | Bryhali | N/A | |||
| Newfoundland and Labrador | Prescription Topical Treatments | Roflumilast | Zoryve | No | N/A | ||
| Newfoundland and Labrador | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00075118.PDF | |
| Newfoundland and Labrador | Biologics and Biosimilars | Ixekizumab | Taltz® | SA | SA | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| Newfoundland and Labrador | Systemic Drugs | Methotrexate | Yes | Yes | |||
| Newfoundland and Labrador | Biologics and Biosimilars | Risankizumab | Skyrizi™ | SA | No | https://pdf.hres.ca/dpd_pm/00075159.PDF | |
| Newfoundland and Labrador | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | SA | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| Newfoundland and Labrador | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | SA | N/A | https://pdf.hres.ca/dpd_pm/00064464.PDF | |
| Newfoundland and Labrador | Systemic Drugs | Tofacitinib | Xeljanz® | N/A | No | https://pdf.hres.ca/dpd_pm/00075206.PDF | |
| Newfoundland and Labrador | Prescription Topical Treatments | Topical Retinoids (Tazarotene) | Arazlo | No | N/A | No information available | |
| Newfoundland and Labrador | Systemic Drugs | Upadacitinib | Rinvoq® | N/A | SA | https://pdf.hres.ca/dpd_pm/00073108.PDF | |
| Newfoundland and Labrador | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| Newfoundland and Labrador | Biologics and Biosimilars | Spesolimab | Spevigo | N/A | N/A | No | |
| Newfoundland and Labrador | Prescription Topical Treatments | Vitamin_D3_Analogues (Calciptriol) | Dovonex® | Yes | N/A | https://pdf.hres.ca/dpd_pm/00064010.PDF | |
| Newfoundland and Labrador | Prescription Topical Treatments | Vitamin_D3_Analogues (Calcitriol) | Silkis® | Yes - generics only | N/A | https://pdf.hres.ca/dpd_pm/00041695.PDF | |
| NIHB | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | https://pdf.hres.ca/dpd_pm/00070861.PDF | |
| NIHB | Systemic Drugs | Acitretin | Soriatane® | Yes | N/A | https://pdf.hres.ca/dpd_pm/00046848.PDF | |
| NIHB | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00067414.PDF | |
| NIHB | Systemic Drugs | Apremilast | Otezla® | No | N/A | https://pdf.hres.ca/dpd_pm/00057499.PDF | |
| NIHB | Biologics and Biosimilars | Bimekizumab | Bimzelx | No | No | https://pdf.hres.ca/dpd_pm/00074908.PDF | |
| NIHB | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – L/U | N/A | https://pdf.hres.ca/dpd_pm/00075300.PDF | |
| NIHB | Prescription Topical Treatments | Halobetasol propionate | Bryhali | N/A | |||
| NIHB | Prescription Topical Treatments | Roflumilast | Zoryve | No | N/A | ||
| NIHB | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – L/U | https://pdf.hres.ca/dpd_pm/00053920.PDF | |
| NIHB | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | Yes | N/A | https://pdf.hres.ca/dpd_pm/00055197.PDF | |
| NIHB | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | Yes | N/A | https://pdf.hres.ca/dpd_pm/00034364.PDF | |
| NIHB | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | Yes | N/A | https://pdf.hres.ca/dpd_pm/00065877.PDF | |
| NIHB | Systemic Drugs | Cyclosporine | Neoral | Yes | N/A | ||
| NIHB | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00060454.PDF | |
| NIHB | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – L/U | https://pdf.hres.ca/dpd_pm/00074084.PDF | |
| NIHB | Biologics and Biosimilars | Guselkumab | Tremfya® | Yes - L/U | Yes - L/U | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| NIHB | Prescription Topical Treatments | Halobetasol propionate and tazarotene | Duobrii® | Yes | N/A | https://pdf.hres.ca/dpd_pm/00066402.PDF | |
| NIHB | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00075118.PDF | |
| NIHB | Biologics and Biosimilars | Ixekizumab | Taltz® | SA | SA | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| NIHB | Systemic Drugs | Methotrexate | Yes | Yes | |||
| NIHB | Biologics and Biosimilars | Risankizumab | Skyrizi™ | SA | No | https://pdf.hres.ca/dpd_pm/00075159.PDF | |
| NIHB | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | SA | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| NIHB | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | SA | N/A | https://pdf.hres.ca/dpd_pm/00064464.PDF | |
| NIHB | Systemic Drugs | Tofacitinib | Xeljanz® | N/A | No | https://pdf.hres.ca/dpd_pm/00075206.PDF | |
| NIHB | Prescription Topical Treatments | Topical Retinoids (Tazarotene) | Arazlo | Yes | N/A | No information available | |
| NIHB | Systemic Drugs | Upadacitinib | Rinvoq® | N/A | SA | https://pdf.hres.ca/dpd_pm/00073108.PDF | |
| NIHB | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| NIHB | Prescription Topical Treatments | Vitamin_D3_Analogues(Calcipotriol) | Dovonex® | Yes | N/A | https://pdf.hres.ca/dpd_pm/00064010.PDF | |
| NIHB | Prescription Topical Treatments | Vitamin_D3_Analogues(Calcitriol) | Silkis® | Yes | N/A | https://pdf.hres.ca/dpd_pm/00041695.PDF | |
| NIHB | Biologics and Biosimilars | Spesolimab | Spevigo | N/A | N/A | No | |
| Northwest Territories | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | https://pdf.hres.ca/dpd_pm/00070861.PDF | |
| Northwest Territories | Systemic Drugs | Acitretin | Soriatane® | Yes | N/A | https://pdf.hres.ca/dpd_pm/00046848.PDF | |
| Northwest Territories | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00067414.PDF | |
| Northwest Territories | Systemic Drugs | Apremilast | Otezla® | No | N/A | https://pdf.hres.ca/dpd_pm/00057499.PDF | |
| Northwest Territories | Biologics and Biosimilars | Bimekizumab | Bimzelx | No | No | https://pdf.hres.ca/dpd_pm/00074908.PDF | |
| Northwest Territories | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – L/U | N/A | https://pdf.hres.ca/dpd_pm/00075300.PDF | |
| Northwest Territories | Prescription Topical Treatments | Halobetasol propionate | Bryhali | N/A | |||
| Northwest Territories | Prescription Topical Treatments | Roflumilast | Zoryve | No | N/A | ||
| Northwest Territories | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – L/U | https://pdf.hres.ca/dpd_pm/00053920.PDF | |
| Northwest Territories | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | Yes | N/A | https://pdf.hres.ca/dpd_pm/00055197.PDF | |
| Northwest Territories | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | Yes | N/A | https://pdf.hres.ca/dpd_pm/00034364.PDF | |
| Northwest Territories | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | Yes | N/A | https://pdf.hres.ca/dpd_pm/00065877.PDF | |
| Northwest Territories | Systemic Drugs | Cyclosporine | Neoral | Yes | N/A | ||
| Northwest Territories | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00060454.PDF | |
| Northwest Territories | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – L/U | https://pdf.hres.ca/dpd_pm/00074084.PDF | |
| Northwest Territories | Biologics and Biosimilars | Guselkumab | Tremfya® | Yes - L/U | Yes - L/U | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| Northwest Territories | Prescription Topical Treatments | Halobetasol propionate and tazarotene | Duobrii® | Yes | N/A | https://pdf.hres.ca/dpd_pm/00066402.PDF | |
| Northwest Territories | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00075118.PDF | |
| Northwest Territories | Biologics and Biosimilars | Ixekizumab | Taltz® | SA | SA | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| Northwest Territories | Systemic Drugs | Methotrexate | Yes | Yes | |||
| Northwest Territories | Biologics and Biosimilars | Risankizumab | Skyrizi™ | SA | No | https://pdf.hres.ca/dpd_pm/00075159.PDF | |
| Northwest Territories | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | SA | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| Northwest Territories | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | SA | N/A | https://pdf.hres.ca/dpd_pm/00064464.PDF | |
| Northwest Territories | Systemic Drugs | Tofacitinib | Xeljanz® | N/A | No | https://pdf.hres.ca/dpd_pm/00075206.PDF | |
| Northwest Territories | Prescription Topical Treatments | Topical Retinoids (Tazarotene) | Arazlo | Yes | N/A | No information available | |
| Northwest Territories | Systemic Drugs | Upadacitinib | Rinvoq® | N/A | SA | https://pdf.hres.ca/dpd_pm/00073108.PDF | |
| Northwest Territories | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| Northwest Territories | Prescription Topical Treatments | Vitamin_D3_Analogues(Calcipotriol) | Dovonex® | Yes | N/A | https://pdf.hres.ca/dpd_pm/00073953.PDF | |
| Northwest Territories | Prescription Topical Treatments | Vitamin_D3_Analogues(Calcitriol) | Silkis® | Yes | N/A | https://pdf.hres.ca/dpd_pm/00064010.PDF | |
| Northwest Territories | Biologics and Biosimilars | Spesolimab | Spevigo | N/A | N/A | No | https://pdf.hres.ca/dpd_pm/00041695.PDF |
| Nova Scotia | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | https://pdf.hres.ca/dpd_pm/00070861.PDF | |
| Nova Scotia | Systemic Drugs | Acitretin | Soriatane® | Yes | N/A | https://pdf.hres.ca/dpd_pm/00046848.PDF | |
| Nova Scotia | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00067414.PDF | |
| Nova Scotia | Systemic Drugs | Apremilast | Otezla® | Yes | Yes | https://pdf.hres.ca/dpd_pm/00057499.PDF | |
| Nova Scotia | Biologics and Biosimilars | Bimekizumab | Bimzelx | Yes – EDS | No | https://pdf.hres.ca/dpd_pm/00074908.PDF | |
| Nova Scotia | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – EDS | N/A | https://pdf.hres.ca/dpd_pm/00075300.PDF | |
| Nova Scotia | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | SA | https://pdf.hres.ca/dpd_pm/00053920.PDF | |
| Nova Scotia | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | SA | N/A | https://pdf.hres.ca/dpd_pm/00055197.PDF | |
| Nova Scotia | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | No | N/A | https://pdf.hres.ca/dpd_pm/00034364.PDF | |
| Nova Scotia | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | SA | N/A | https://pdf.hres.ca/dpd_pm/00065877.PDF | |
| Nova Scotia | Systemic Drugs | Cyclosporine | Neoral | Yes | Yes | ||
| Nova Scotia | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00060454.PDF | |
| Nova Scotia | Biologics and Biosimilars | Golimumab | Simponi® | SA | SA | https://pdf.hres.ca/dpd_pm/00074084.PDF | |
| Nova Scotia | Biologics and Biosimilars | Guselkumab | Tremfya® | Yes – EDS | Yes – EDS | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| Nova Scotia | Prescription Topical Treatments | Halobetasol propionate and tazarotene | Duobrii® | SA | N/A | https://pdf.hres.ca/dpd_pm/00066402.PDF | |
| Nova Scotia | Prescription Topical Treatments | Halobetasol propionate | Bryhali | N/A | |||
| Nova Scotia | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00075118.PDF | |
| Nova Scotia | Biologics and Biosimilars | Ixekizumab | Taltz | SA | SA | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| Nova Scotia | Systemic Drugs | Methotrexate | Yes | N/A | |||
| Nova Scotia | Biologics and Biosimilars | Risankizumab | Skyrizi™ | SA | No | https://pdf.hres.ca/dpd_pm/00075159.PDF | |
| Nova Scotia | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | SA | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| Nova Scotia | Prescription Topical Treatments | Roflumilast | Zoryve | No | N/A | ||
| Nova Scotia | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | SA | N/A | https://pdf.hres.ca/dpd_pm/00064464.PDF | |
| Nova Scotia | Systemic Drugs | Tofacitinib | Xeljanz® | N/A | No | https://pdf.hres.ca/dpd_pm/00075206.PDF | |
| Nova Scotia | Prescription Topical Treatments | Topical Retinoids (Tazarotene) | Arazlo | SA | N/A | No information available | |
| Nova Scotia | Systemic Drugs | Upadacitinib | Rinvoq® | N/A | SA | https://pdf.hres.ca/dpd_pm/00073108.PDF | |
| Nova Scotia | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| Nova Scotia | Prescription Topical Treatments | Vitamin_D3_Analogues(Calcipotriol ) | Dovonex® | SA | N/A | https://pdf.hres.ca/dpd_pm/00064010.PDF | |
| Nova Scotia | Prescription Topical Treatments | Vitamin_D3_Analogues(Calcitriol ) | Silkis® | Yes | N/A | https://pdf.hres.ca/dpd_pm/00041695.PDF | |
| Nova Scotia | Biologics and Biosimilars | spesolimab | Spevigo | N/A | N/A | No | |
| Nunavut | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | https://pdf.hres.ca/dpd_pm/00070861.PDF | |
| Nunavut | Systemic Drugs | Acitretin | Soriatane® | Yes | N/A | https://pdf.hres.ca/dpd_pm/00046848.PDF | |
| Nunavut | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00067414.PDF | |
| Nunavut | Systemic Drugs | Apremilast | Otezla® | No | N/A | https://pdf.hres.ca/dpd_pm/00057499.PDF | |
| Nunavut | Biologics and Biosimilars | Bimekizumab | Bimzelx | No | No | https://pdf.hres.ca/dpd_pm/00074908.PDF | |
| Nunavut | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – L/U | N/A | https://pdf.hres.ca/dpd_pm/00075300.PDF | |
| Nunavut | Prescription Topical Treatments | Halobetasol propionate | Bryhali | N/A | |||
| Nunavut | Prescription Topical Treatments | Roflumilast | Zoryve | No | N/A | ||
| Nunavut | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – L/U | https://pdf.hres.ca/dpd_pm/00053920.PDF | |
| Nunavut | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | Yes | N/A | https://pdf.hres.ca/dpd_pm/00055197.PDF | |
| Nunavut | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | Yes | N/A | https://pdf.hres.ca/dpd_pm/00034364.PDF | |
| Nunavut | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | Yes | N/A | https://pdf.hres.ca/dpd_pm/00065877.PDF | |
| Nunavut | Systemic Drugs | Cyclosporine | Neoral | Yes | N/A | ||
| Nunavut | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00060454.PDF | |
| Nunavut | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – L/U | https://pdf.hres.ca/dpd_pm/00074084.PDF | |
| Nunavut | Biologics and Biosimilars | Guselkumab | Tremfya® | Yes - L/U | Yes - L/U | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| Nunavut | Prescription Topical Treatments | Halobetasol propionate and tazarotene | Duobrii® | Yes | N/A | https://pdf.hres.ca/dpd_pm/00066402.PDF | |
| Nunavut | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00075118.PDF | |
| Nunavut | Biologics and Biosimilars | Ixekizumab | Taltz® | SA | SA | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| Nunavut | Systemic Drugs | Methotrexate | Yes | Yes | |||
| Nunavut | Biologics and Biosimilars | Risankizumab | Skyrizi™ | SA | No | https://pdf.hres.ca/dpd_pm/00075159.PDF | |
| Nunavut | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | SA | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| Nunavut | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | SA | N/A | https://pdf.hres.ca/dpd_pm/00064464.PDF | |
| Nunavut | Systemic Drugs | Tofacitinib | Xeljanz® | N/A | No | https://pdf.hres.ca/dpd_pm/00075206.PDF | |
| Nunavut | Prescription Topical Treatments | Topical Retinoids (Tazarotene) | Arazlo | Yes | N/A | No information available | |
| Nunavut | Systemic Drugs | Upadacitinib | Rinvoq® | N/A | SA | https://pdf.hres.ca/dpd_pm/00073108.PDF | |
| Nunavut | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| Nunavut | Prescription Topical Treatments | Vitamin_D3_Analogues(Calcipotriol) | Dovonex® | Yes | N/A | https://pdf.hres.ca/dpd_pm/00073953.PDF | |
| Nunavut | Prescription Topical Treatments | Vitamin_D3_Analogues(Calcitriol) | Silkis® | Yes | N/A | https://pdf.hres.ca/dpd_pm/00064010.PDF | |
| Nunavut | Biologics and Biosimilars | Spesolimab | Spevigo | N/A | N/A | No | https://pdf.hres.ca/dpd_pm/00041695.PDF |
| Ontario | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | https://pdf.hres.ca/dpd_pm/00070861.PDF | |
| Ontario | Systemic Drugs | Acitretin | Soriatane® | Yes | N/A | https://pdf.hres.ca/dpd_pm/00046848.PDF | |
| Ontario | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00068228.PDF | |
| Ontario | Systemic Drugs | Apremilast | Otezla® | Yes | Yes | https://pdf.hres.ca/dpd_pm/00057499.PDF | |
| Ontario | Biologics and Biosimilars | Bimekizumab | Bimzelx | Yes - L/U | No | https://pdf.hres.ca/dpd_pm/00074908.PDF | |
| Ontario | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – L/U | N/A | https://pdf.hres.ca/dpd_pm/00075300.PDF | |
| Ontario | Prescription Topical Treatments | Halobetasol propionate | Bryhali | N/A | |||
| Ontario | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – EAP | https://pdf.hres.ca/dpd_pm/00053920.PDF | |
| Ontario | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | Yes – in specific clinical situations | N/A | https://pdf.hres.ca/dpd_pm/00055197.PDF | |
| Ontario | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | Yes – in specific clinical situations | N/A | https://pdf.hres.ca/dpd_pm/00034364.PDF | |
| Ontario | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | Yes – in specific clinical situations | N/A | https://pdf.hres.ca/dpd_pm/00065877.PDF | |
| Ontario | Systemic Drugs | Cyclosporine | Neoral | Yes | N/A | ||
| Ontario | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00065129.PDF | |
| Ontario | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes - EAP | https://pdf.hres.ca/dpd_pm/00074084.PDF | |
| Ontario | Biologics and Biosimilars | Guselkumab | Tremfya® | Yes - L/U | Yes - EAP | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| Ontario | Prescription Topical Treatments | Halobetasol propionate and tazarotene | Duobrii® | Yes | N/A | https://pdf.hres.ca/dpd_pm/00066402.PDF | |
| Ontario | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00065940.PDF | |
| Ontario | Biologics and Biosimilars | Ixekizumab | Taltz® | SA | No | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| Ontario | Systemic Drugs | Methotrexate | Yes | Yes | |||
| Ontario | Biologics and Biosimilars | Risankizumab | Skyrizi™ | SA | No | https://pdf.hres.ca/dpd_pm/00075159.PDF | |
| Ontario | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | No | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| Ontario | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | SA | N/A | https://pdf.hres.ca/dpd_pm/00064464.PDF | |
| Ontario | Systemic Drugs | Tofacitinib | Xeljanz® | N/A | No | https://pdf.hres.ca/dpd_pm/00075206.PDF | |
| Ontario | Prescription Topical Treatments | Topical Retinoids (Tazarotene) | Arazlo | No | N/A | No information available | |
| Ontario | Systemic Drugs | Upadacitinib | Rinvoq® | SA | No | https://pdf.hres.ca/dpd_pm/00073108.PDF | |
| Ontario | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| Ontario | Prescription Topical Treatments | Vitamin_D3_Analogues(Calcipotriol) | Dovonex® | SA | N/A | https://pdf.hres.ca/dpd_pm/00064010.PDF | |
| Ontario | Prescription Topical Treatments | Vitamin_D3_Analogues(Calcitriol) | Silkis | Yes | N/A | https://pdf.hres.ca/dpd_pm/00041695.PDF | |
| Ontario | Biologics and Biosimilars | spesolimab | Spevigo | N/A | N/A | No | |
| Prince Edward Island | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | https://pdf.hres.ca/dpd_pm/00070861.PDF | |
| Prince Edward Island | Systemic Drugs | Acitretin | Soriatane® | Yes | N/A | https://pdf.hres.ca/dpd_pm/00046848.PDF | |
| Prince Edward Island | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00067414.PDF | |
| Prince Edward Island | Systemic Drugs | Apremilast | Otezla® | No | No | https://pdf.hres.ca/dpd_pm/00057499.PDF | |
| Prince Edward Island | Biologics and Biosimilars | Bimekizumab | Bimzelx | Yes – S/A | No | https://pdf.hres.ca/dpd_pm/00074908.PDF | |
| Prince Edward Island | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – S/A | N/A | https://pdf.hres.ca/dpd_pm/00075300.PDF | |
| Prince Edward Island | Prescription Topical Treatments | halobetasol propionate | Bryhali | N/A | |||
| Prince Edward Island | Prescription Topical Treatments | Roflumilast | Zoryve | No | N/A | ||
| Prince Edward Island | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – S/A | https://pdf.hres.ca/dpd_pm/00053920.PDF | |
| Prince Edward Island | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | Yes | N/A | https://pdf.hres.ca/dpd_pm/00055197.PDF | |
| Prince Edward Island | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | Yes | N/A | https://pdf.hres.ca/dpd_pm/00034364.PDF | |
| Prince Edward Island | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | Yes | N/A | https://pdf.hres.ca/dpd_pm/00065877.PDF | |
| Prince Edward Island | Systemic Drugs | Cyclosporine | Neoral | Yes | N/A | ||
| Prince Edward Island | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00060454.PDF | |
| Prince Edward Island | Biologics and Biosimilars | Golimumab | Simponi® | No | Yes – S/A | https://pdf.hres.ca/dpd_pm/00074084.PDF | |
| Prince Edward Island | Biologics and Biosimilars | Guselkumab | Tremfya® | Yes – S/A | Yes – S/A | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| Prince Edward Island | Prescription Topical Treatments | Halobetasol propionate and tazarotene | Duobrii® | No | N/A | https://pdf.hres.ca/dpd_pm/00066402.PDF | |
| Prince Edward Island | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00075118.PDF | |
| Prince Edward Island | Biologics and Biosimilars | Ixekizumab | Taltz® | SA | SA | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| Prince Edward Island | Systemic Drugs | Methotrexate | Yes | Yes | |||
| Prince Edward Island | Biologics and Biosimilars | Risankizumab | Skyrizi™ | SA | No | https://pdf.hres.ca/dpd_pm/00075159.PDF | |
| Prince Edward Island | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | SA | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| Prince Edward Island | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | SA | N/A | https://pdf.hres.ca/dpd_pm/00064464.PDF | |
| Prince Edward Island | Systemic Drugs | Tofacitinib | Xeljanz® | N/A | No | https://pdf.hres.ca/dpd_pm/00075206.PDF | |
| Prince Edward Island | Prescription Topical Treatments | Topical Retinoids (Tazarotene) | Arazlo | Yes | N/A | No information available | |
| Prince Edward Island | Systemic Drugs | Upadacitinib | Rinvoq® | N/A | SA | https://pdf.hres.ca/dpd_pm/00073108.PDF | |
| Prince Edward Island | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| Prince Edward Island | Prescription Topical Treatments | Vitamin_D3_Analogues(Calcipotriol) | Dovonex® | Yes | N/A | https://pdf.hres.ca/dpd_pm/00064010.PDF | |
| Prince Edward Island | Prescription Topical Treatments | Vitamin_D3_Analogues(Calcitriol) | Silkis® | Yes | N/A | https://pdf.hres.ca/dpd_pm/00041695.PDF | |
| Prince Edward Island | Biologics and Biosimilars | spesolimab | Spevigo | N/A | N/A | No | |
| Quebec | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | https://pdf.hres.ca/dpd_pm/00070861.PDF | |
| Quebec | Systemic Drugs | Acitretin | Soriatane® | Yes | N/A | https://pdf.hres.ca/dpd_pm/00046848.PDF | |
| Quebec | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00067414.PDF | |
| Quebec | Systemic Drugs | Apremilast | Otezla® | SA | No | https://pdf.hres.ca/dpd_pm/00057499.PDF | |
| Quebec | Biologics and Biosimilars | Bimekizumab | Bimzelx | Yes – S/A | No | https://pdf.hres.ca/dpd_pm/00074908.PDF | |
| Quebec | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – S/A | N/A | https://pdf.hres.ca/dpd_pm/00075300.PDF | |
| Quebec | Prescription Topical Treatments | Halobetasol propionate | Bryhali | N/A | |||
| Quebec | Prescription Topical Treatments | Roflumilast | Zoryve | No | N/A | ||
| Quebec | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – S/A | https://pdf.hres.ca/dpd_pm/00053920.PDF | |
| Quebec | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | SA | N/A | https://pdf.hres.ca/dpd_pm/00055197.PDF | |
| Quebec | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | SA | N/A | https://pdf.hres.ca/dpd_pm/00034364.PDF | |
| Quebec | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | SA | N/A | https://pdf.hres.ca/dpd_pm/00065877.PDF | |
| Quebec | Systemic Drugs | Cyclosporine | Neoral | Yes | N/A | ||
| Quebec | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00060454.PDF | |
| Quebec | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – S/A | https://pdf.hres.ca/dpd_pm/00074084.PDF | |
| Quebec | Biologics and Biosimilars | Guselkumab | Tremfya® | Yes - S/A | No | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| Quebec | Prescription Topical Treatments | Halobetasol propionate and tazarotene | Duobrii® | Yes - S/A | N/A | https://pdf.hres.ca/dpd_pm/00066402.PDF | |
| Quebec | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00075118.PDF | |
| Quebec | Biologics and Biosimilars | Ixekizumab | Taltz® | SA | SA | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| Quebec | Systemic Drugs | Methotrexate | Yes | Yes | |||
| Quebec | Biologics and Biosimilars | Risankizumab | Skyrizi™ | SA | No | https://pdf.hres.ca/dpd_pm/00075159.PDF | |
| Quebec | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | SA | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| Quebec | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | SA | N/A | https://pdf.hres.ca/dpd_pm/00064464.PDF | |
| Quebec | Systemic Drugs | Tofacitinib | Xeljanz® | N/A | No | https://pdf.hres.ca/dpd_pm/00075206.PDF | |
| Quebec | Prescription Topical Treatments | Topical Retinoids (Tazarotene) | Arazlo | No | N/A | No information available | |
| Quebec | Systemic Drugs | Upadacitinib | Rinvoq® | N/A | SA | https://pdf.hres.ca/dpd_pm/00073108.PDF | |
| Quebec | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| Quebec | Prescription Topical Treatments | Vitamin_D3_Analogues(Calcipotriol) | Dovonex® | Yes | N/A | https://pdf.hres.ca/dpd_pm/00064010.PDF | |
| Quebec | Prescription Topical Treatments | Vitamin_D3_Analogues(Calcitriol) | Silkis® | Yes | N/A | https://pdf.hres.ca/dpd_pm/00041695.PDF | |
| Quebec | Biologics and Biosimilars | Spesolimab | Spevigo | N/A | N/A | No | |
| Saskatchewan | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | https://pdf.hres.ca/dpd_pm/00070861.PDF | |
| Saskatchewan | Systemic Drugs | Acitretin | Soriatane® | SA | N/A | https://pdf.hres.ca/dpd_pm/00046848.PDF | |
| Saskatchewan | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00067414.PDF | |
| Saskatchewan | Systemic Drugs | Apremilast | Otezla® | No | No | https://pdf.hres.ca/dpd_pm/00057499.PDF | |
| Saskatchewan | Biologics and Biosimilars | Bimekizumab | Bimzelx | https://pdf.hres.ca/dpd_pm/00074908.PDF | |||
| Saskatchewan | Biologics and Biosimilars | Brodalumab | Siliq™ | https://pdf.hres.ca/dpd_pm/00075300.PDF | |||
| Saskatchewan | Prescription Topical Treatments | Halobetasol propionate | Bryhali | N/A | |||
| Saskatchewan | Prescription Topical Treatments | Roflumilast | Zoryve | No | N/A | ||
| Saskatchewan | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | https://pdf.hres.ca/dpd_pm/00053920.PDF | |||
| Saskatchewan | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | Yes | N/A | https://pdf.hres.ca/dpd_pm/00055197.PDF | |
| Saskatchewan | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | Yes | N/A | https://pdf.hres.ca/dpd_pm/00034364.PDF | |
| Saskatchewan | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | Yes | N/A | https://pdf.hres.ca/dpd_pm/00065877.PDF | |
| Saskatchewan | Systemic Drugs | Cyclosporine | Neoral | SA | N/A | ||
| Saskatchewan | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00060454.PDF | |
| Saskatchewan | Biologics and Biosimilars | Golimumab | Simponi® | No | Yes – EDS | https://pdf.hres.ca/dpd_pm/00074084.PDF | |
| Saskatchewan | Biologics and Biosimilars | Guselkumab | Tremfya® | Yes - EDS | Yes - EDS | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| Saskatchewan | Prescription Topical Treatments | Halobetasol propionate and tazarotene | Duobrii® | Yes | N/A | https://pdf.hres.ca/dpd_pm/00066402.PDF | |
| Saskatchewan | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00075118.PDF | |
| Saskatchewan | Biologics and Biosimilars | Ixekizumab | Taltz® | SA | SA | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| Saskatchewan | Systemic Drugs | Methotrexate | Yes | Yes | |||
| Saskatchewan | Biologics and Biosimilars | Risankizumab | Skyrizi™ | SA | No | https://pdf.hres.ca/dpd_pm/00075159.PDF | |
| Saskatchewan | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | SA | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| Saskatchewan | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | SA | N/A | https://pdf.hres.ca/dpd_pm/00064464.PDF | |
| Saskatchewan | Systemic Drugs | Tofacitinib | Xeljanz® | N/A | No | https://pdf.hres.ca/dpd_pm/00075206.PDF | |
| Saskatchewan | Prescription Topical Treatments | Topical Retinoids (Tazarotene) | Arazlo | Yes | N/A | No information available | |
| Saskatchewan | Systemic Drugs | Upadacitinib | Rinvoq® | N/A | SA | https://pdf.hres.ca/dpd_pm/00073108.PDF | |
| Saskatchewan | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| Saskatchewan | Prescription Topical Treatments | Vitamin_D3_Analogues(Calcipotriol) | Dovonex® | Yes | N/A | https://pdf.hres.ca/dpd_pm/00064010.PDF | |
| Saskatchewan | Prescription Topical Treatments | Vitamin_D3_Analogues(Calcitriol) | Silkis® | No | N/A | https://pdf.hres.ca/dpd_pm/00041695.PDF | |
| Saskatchewan | Biologics and Biosimilars | Spesolimab | Spevigo | N/A | N/A | No | |
| Yukon | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | https://pdf.hres.ca/dpd_pm/00070861.PDF | |
| Yukon | Systemic Drugs | Acitretin | Soriatane® | SA | N/A | https://pdf.hres.ca/dpd_pm/00046848.PDF | |
| Yukon | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00067414.PDF | |
| Yukon | Systemic Drugs | Apremilast | Otezla | No | No | https://pdf.hres.ca/dpd_pm/00057499.PDF | |
| Yukon | Biologics and Biosimilars | Bimekizumab | Bimzelx | No | No | https://pdf.hres.ca/dpd_pm/00074908.PDF | |
| Yukon | Prescription Topical Treatments | halobetasol propionate | Bryhali | N/A | |||
| Yukon | Prescription Topical Treatments | Roflumilast | Zoryve | No | N/A | ||
| Yukon | Biologics and Biosimilars | Brodalumab | Siliq™ | No | N/A | https://pdf.hres.ca/dpd_pm/00075300.PDF | |
| Yukon | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – EDS | https://pdf.hres.ca/dpd_pm/00053920.PDF | |
| Yukon | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | Yes | N/A | https://pdf.hres.ca/dpd_pm/00055197.PDF | |
| Yukon | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | Yes | N/A | https://pdf.hres.ca/dpd_pm/00034364.PDF | |
| Yukon | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | Yes | N/A | https://pdf.hres.ca/dpd_pm/00065877.PDF | |
| Yukon | Systemic Drugs | Cyclosporine | Neoral | Yes | N/A | ||
| Yukon | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00060454.PDF | |
| Yukon | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – EDS | https://pdf.hres.ca/dpd_pm/00074084.PDF | |
| Yukon | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| Yukon | Prescription Topical Treatments | Halobetasol propionate and tazarotene | Duobrii® | No | N/A | https://pdf.hres.ca/dpd_pm/00066402.PDF | |
| Yukon | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00075118.PDF | |
| Yukon | Biologics and Biosimilars | Ixekizumab | Taltz® | SA | SA | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| Yukon | Systemic Drugs | Methotrexate | Yes | Yes | |||
| Yukon | Biologics and Biosimilars | Risankizumab | Skyrizi™ | SA | No | https://pdf.hres.ca/dpd_pm/00075159.PDF | |
| Yukon | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | SA | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| Yukon | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | No | N/A | https://pdf.hres.ca/dpd_pm/00064464.PDF | |
| Yukon | Systemic Drugs | Tofacitinib | Xeljanz® | N/A | No | https://pdf.hres.ca/dpd_pm/00075206.PDF | |
| Yukon | Prescription Topical Treatments | Topical Retinoids (Tazarotene) | Arazlo | Yes | N/A | No information available | |
| Yukon | Systemic Drugs | Upadacitinib | Rinvoq® | SA | Yes - SA | https://pdf.hres.ca/dpd_pm/00073108.PDF | |
| Yukon | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| Yukon | Prescription Topical Treatments | Vitamin_D3_Analogues(Calcipotriol) | Dovonex® | Yes | N/A | https://pdf.hres.ca/dpd_pm/00064010.PDF | |
| Yukon | Prescription Topical Treatments | Vitamin_D3_Analogues(Calcitriol) | Silkis® | Yes | N/A | https://pdf.hres.ca/dpd_pm/00041695.PDF | |
| Yukon | Biologics and Biosimilars | Spesolimab | Spevigo | N/A | N/A | No |